Table 5.

Univariate analysis of time to recurrence (TTR), cancer-specific survival (CSS), and overall survival (OS) according to blood hemoglobin levels with different cut-off points, erythrocyte mean corpuscular volume (MCV), and different anemia categories.

Variable	TTRA			CSSB			OSC
	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value
Cohort 1
Blood hemoglobin
<110 g/L vs. ≥ 110 g/L	0.79	0.43–1.45	0.444	0.66	0.39–1.12	0.119	0.64	0.42–0.99	0.045
<120 g/L vs. ≥ 120 g/L	1.39	0.79–2.45	0.257	0.70	0.44–1.11	0.132	0.65	0.44–0.95	0.026
<130 g/L vs. ≥ 130 g/L	1.30	0.79–2.13	0.301	0.61	0.38–0.97	0.037	0.59	0.40–0.87	0.008
<140 g/L vs. ≥ 140 g/L	1.06	0.62–1.84	0.829	0.37	0.19–0.75	0.005	0.46	0.27–0.78	0.004
Erythrocyte mean corpuscular volume (MCV)
<80 fL vs. ≥ 80 fL	1.14	0.54–2.40	0.726	1.16	0.58–2.32	0.682	1.28	0.70–2.33	0.422
<90 fL vs. ≥ 90 fL	1.09	0.67–1.80	0.722	0.91	0.57–1.44	0.683	1.12	0.77–1.64	0.542
Anemia
No vs. Yes	0.74	0.44–1.24	0.252	1.26	0.80–1.98	0.320	1.44	0.99–2.10	0.055
Microcytic anemia
No vs. Yes	0.91	0.43–1.91	0.798	0.80	0.38–1.66	0.546	0.75	0.40–1.40	0.363
Normocytic anemia
No vs. Yes	0.67	0.36–1.23	0.194	1.39	0.87–2.24	0.171	1.69	1.15–2.48	0.007

^An = 299; median follow-up time 51.2 months (IQR 24.7–71.4); 63 (21.0%) events; 57 (16.0%) cases excluded from the analysis because the operation was not radical or no follow-up data available.

^Bn = 354; median follow-up time 56.0 months (IQR 32.9–78.6); 75 (21.2%) events; 2 (0.6%) cases excluded from the analysis because no follow-up data available.

^Cn = 356; median follow-up time 56.0 months (IQR 32.9–78.6); 110 (30.9%) events.

Abbreviations: CI: confidence interval; CSS: cancer specific survival; HR: hazard ratio; OS: overall survival; TTR: time to recurrence.